BILLERICA, Mass., Oct. 26, 2015 /PRNewswire/ -- EMD Millipore, the Life Science business of Merck KGaA of Darmstadt, Germany, today introduced Parteck® SRP 80, a new functional excipient for oral sustained-release formulations. Parteck® SRP 80 is a polyvinyl alcohol (PVA) based excipient specifically designed for modified-release applications, for optimization of pharmacokinetics and pharmacodynamics as well as the bioavailability of actives. The new excipient is fully synthetic, ensuring batch-to-batch and performance consistency and facilitating quality by design (QbD) and validation processes.
Suitable for direct compression processes, Parteck® SRP 80 allows for fast, easy and efficient formulation development as well as production processes. Parteck® SRP 80 is compliant with European Pharmacopoeia (Ph. Eur.), United States Pharmacopoeia (USP) and Japanese Pharmacopoeia Excipients (JPE) and will be part of EMD Millipore's Emprove® program to facilitate regulatory filing and registration processes.
"Pharmaceutical excipients play an essential role in the development of safe and effective medicines," said Andrew Bulpin, Executive Vice President of Process Solutions, EMD Millipore. "Parteck® SRP 80 represents a new choice for customers looking to formulate prolonged release oral dosage forms with reliable performance profiles as well as robust and cost efficient production processes, which can translate into improved patient safety and compliance."
Experts from Merck Millipore will be available at booth #1636 at the 2015 American Association of Pharmaceutical Scientists (AAPS) Annual Conference in Orlando, Florida to discuss Parteck® SRP 80 and the entire Emprove® portfolio.
About EMD Millipore
EMD Millipore is the U.S. Life Science subsidiary of Merck KGaA, Darmstadt, Germany. As part of the global Life Science business of Merck KGaA, Darmstadt, Germany, EMD Millipore offers a broad range of innovative, performance products, services and business relationships that enable our customers' success in research, development and production of biotech and pharmaceutical drug therapies. Through dedicated collaboration on new scientific and engineering insights, and as one of the top three R&D investors in the life science tools industry, the Life Science business of Merck KGaA, Darmstadt, Germany, serves as a strategic partner to customers and helps advance the promise of life science. Headquartered in Billerica, Massachusetts, the global business has around 10,000 employees, operations in 66 countries and 2014 revenues of €2.7 billion.
For more information, please visit www.emdmillipore.com.
About Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials. The company has six businesses – Biopharmaceuticals, Consumer Health, Allergopharma, Biosimilars, Life Science and Performance Materials – and generated sales of € 11.3 billion in 2014. Around 39,000 employees work in 66 countries to improve the quality of life for patients, to foster the success of customers and to help meet global challenges. Merck KGaA, Darmstadt, Germany, is the world's oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70% interest, the founding family remains the majority owner of the company to this day. Merck KGaA, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company operates as EMD Serono, EMD Millipore and EMD Performance Materials.
For more information, please visit www.emdgroup.com.
SOURCE EMD Millipore